Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy...
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
About this item
Full title
Author / Creator
Wu, Zhiwei , Hu, Yaling , Xu, Miao , Chen, Zhen , Yang, Wanqi , Jiang, Zhiwei , Li, Minjie , Jin, Hui , Cui, Guoliang , Chen, Panpan , Wang, Lei , Zhao, Guoqing , Ding, Yuzhu , Zhao, Yuliang and Yin, Weidong
Publisher
United States: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
A vaccine against COVID-19 is urgently needed for older adults, in whom morbidity and mortality due to the disease are increased. We aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in adults aged 60 years and older.
We did a randomised, double-blind, plac...
Alternative Titles
Full title
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7906628
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7906628
Other Identifiers
ISSN
1473-3099
E-ISSN
1474-4457
DOI
10.1016/S1473-3099(20)30987-7
